Business Of Biotech

By: Matt Pillar
  • Summary

  • The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, and regulatory challenges you’ll face as you navigate your company from an idea to success in the clinic. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Bioprocess Online and Life Science Connect and brought to you by Cytiva.

    © 2024 Business Of Biotech
    Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • Serving The Underserved With Gates MRI's Claire Wagner, M.D.
    Nov 11 2024

    We love to hear from our listeners. Send us a message.

    On this episode of the Business of Biotech, Bill and Melinda Gates Medical Research Institute's (Gates MRI) Dr. Claire Wagner joins us to share insights into her work as head of Corporate Strategy and Market Access there. She shares the development of her North Star while working with the incomparable Dr. Paul Farmer in Rwanda, and how that experience translates to the growth of a biopharmaceutical company taking big swings for grossly underserved populations. We discuss the nuances assoiated with setting strategy and enabling product access in a unique not-for-profit setting, and how, perhaps counterintutively, the Institute's work fits synergistically into an ultra-competitive for-profit biopharma landscape.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com

    Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/


    Show More Show Less
    47 mins
  • An Unanticipated Biotech Startup With OS Therapies' Paul Romness
    Nov 4 2024

    We love to hear from our listeners. Send us a message.

    Becoming a biotech CEO wasn't on Paul Romness' bingo card. He'd forged his place in the biopharma industry as a foremost public and policy affairs expert. Thirteen years at J&J, more than 5 at Amgen, and half a dozen at Boehringer Ingelheim had earned him the right to coast into a consulting gig that would enable him to finish out his career on his terms.

    Then his daughter's best friend Olivia, a teenage girl and neighbor he'd watched grow up, was diagnosed with osteosarcoma.

    The ensuing journey, now in its seventh year, put Romness in the position of CEO and Chair of OS Therapies. It's a company formed through a combination of circumstance, determination, and ingenuity that's now shepherding its HER2 and tunable ADC therapeutics through mid-late-stage clinical trials. On this episode of the Business of Biotech, we dig into the building blocks of an unanticipated biotech startup. We'll learn how Romness leaned into his personal and professional communities to build a company that's now addressing unmet patient need in osteosarcoma and cancers of the breast, esophagus, lung, and pancreas. And we'll get an update on Olivia, who's now in med school at Columbia University and serving on the OS Therapies Board of Directors.


    Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com

    Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/


    Show More Show Less
    49 mins
  • Building On Pandemic Progress With Barinthus Biotherapeutics' Bill Enright
    Oct 28 2024

    We love to hear from our listeners. Send us a message.

    It might just be coincidence, but it sure seems like Bill Enright has a knack for making big moves at inopportune times, then turning the expected outcome on its ear. For example, he signed on as CEO at Altimmune when the company was struggling mightily. Enright had a turnaround plan in hand, but as he was in the thick of a non-deal road show to execute said plan, Lehmen Brothers collapsed. On this episode of the Business of Biotech, we'll learn in great detail how Altimmune escaped that death knell. Later, he joined his current company, Barinthus Biotherapeutics, mere months before the Covid pandemic. That was shaky for a hot minute, but it turned out fortuitous when, against his better judgment, he enabled a pivot that became foundational to the company's go-forward plan. We'll learn how he flipped the script on that crisis, too. Tune in for these, and other harrowing tales from the trenches.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com

    Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/


    Show More Show Less
    44 mins

What listeners say about Business Of Biotech

Average customer ratings
Overall
  • 3 out of 5 stars
  • 5 Stars
    0
  • 4 Stars
    0
  • 3 Stars
    1
  • 2 Stars
    0
  • 1 Stars
    0
Performance
  • 2 out of 5 stars
  • 5 Stars
    0
  • 4 Stars
    0
  • 3 Stars
    0
  • 2 Stars
    1
  • 1 Stars
    0
Story
  • 2 out of 5 stars
  • 5 Stars
    0
  • 4 Stars
    0
  • 3 Stars
    0
  • 2 Stars
    1
  • 1 Stars
    0

Reviews - Please select the tabs below to change the source of reviews.